SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its commitment to building and developing the project, highlighting its staking on BiFinance and Broke Perspective media platform. Despite market dips, the community emphasizes its resilience, ongoing development, and the pursuit of long-term growth on the Solana blockchain. Talk centers on the potential for a resurgence in price action and a push towards a token supply burn at 2500 watchers.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors digest recent earnings and production updates, with community sentiment split between disappointment in the new CEO's presentation and optimism about the company's long-term value given current gold prices. Discussions revolve around whether the recent price action represents a buying opportunity or a sign of deeper issues, with some suggesting potential manipulation to drive down call options. The broader context includes rising gold prices and speculation about potential mergers within the mining sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers (DECK) is trending due to a significant after-hours selloff despite the company reporting better-than-expected earnings, with the community debating whether the dip is a buying opportunity or a sign of deeper issues. The cautious outlook and slowing international growth are raising concerns, while some investors point to the company's buyback program and potential for recovery. Discussions also include the impact of tariffs and comparisons to other companies in the apparel and footwear sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid discussions around trade relations, particularly Trump's stance on Canada, and anticipation of upcoming CPI data which is expected to be a market-moving event. Community sentiment appears mixed, with some expressing skepticism about the market's sustained rally and potential impacts of the government shutdown. Overall, traders are closely watching for signals that could influence the Federal Reserve's next move.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu Traws Pharma Announces...

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program PR Newswire SAN DIEGO, Jan...

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Traws Pharma, Inc...

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu PR Newswire NEWTOWN, Pa., Dec...

Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment

Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir...

Earnings Scheduled For April 16, 2024

Companies Reporting Before The Bell
 Traws Pharma (NASDAQ:TRAW) is expected to report earnings for its fourth quarter.
read more...

Traws Pharma Announces New Employee Inducement Grants

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, Traws , the Company ) today announced it has granted equity awards to new employees who joined Traws in...

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Current Price	$2.63
Prev Close	$2.68
Open	$2.65
Dividend Yield	0.00%
50-Day Moving Average	$2.02
Beta	0.92
Avg. Volume	91,338.76
PE Ratio	0.17

52-Week High	$19.44
52-Week Low	$0.97
Market Capitalization	$18.74M
EPS (Annual)	-$35.21
Price to Book	2.25
Revenue Per Employee	$32,285.71
Enterprise Value/EBITDA	N/A

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRAW News

TRAWTraws Pharma Inc.